Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Arena Pharmaceuticals |
---|---|
Information provided by: | Arena Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00828932 |
The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.
Condition | Intervention | Phase |
---|---|---|
Hepatic Impairment |
Drug: Lorcaserin |
Phase I |
Study Type: | Interventional |
Study Design: | Open Label, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment |
Estimated Enrollment: | 24 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Lorcaserin 10mg: Experimental | Drug: Lorcaserin |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Hepatic function will fall into one of the following categories:
Exclusion Criteria:
History of any of the following cardiovascular conditions:
United States, Florida | |
Orlando Clinical Research Center | |
Orlando, Florida, United States, 32809 |
Investigator: | Christen Anderson, MD, PhD | Arena Pharmaceuticals |
Responsible Party: | Arena Pharmaceuticals, INc. ( Christen Anderson, MD, PhD ) |
Study ID Numbers: | APD356-017 |
Study First Received: | January 22, 2009 |
Last Updated: | January 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00828932 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Liver Diseases Digestive System Diseases |
Liver Diseases Digestive System Diseases |